Luye Pharma Announces 2025 Half-Year Results
- New Product Sales Up 32%, International Strategy Upgraded -
Shanghai, August 28, 2025 -- Luye Pharma Group (2186.HK) today announced its 2025 half-year results and latest developments. During the reporting period, its revenue was about RMB 3181 million, up 3.5% YoY, its EBITDA was about ...
August 28,2025
All Patients Enrolled for the Phase III Clinical Trial of Luye Pharma’s Ruoxinlin® for Treating Generalized Anxiety Disorder
Shanghai, August 18, 2025 –- Luye Pharma Group announced that all patients have been enrolled for a Phase 3 clinical trial of its Ruoxinlin® (Toludesvenlafaxine Hydrochloride Sustained-Release Tablets) designated as a Class 1 innovative drug in China for the treatment of ...
August 18,2025
03
2025-08
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR
10
2025-04
Luye Pharma Launches Its Transdermal Patch Rotigotine Luye in the UK for the Treatment of Parkinson’s Disease and Restless Legs Syndrome
07
2025-04
Luye Pharma’s Class 1 Innovative Antidepressant Ruoxinlin® Approved for Marketing in Macao
07
2025-04
Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
31
2025-03
Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer’s Dementia
14
2025-01
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
03
2024-12
Luye Pharma Announces the Approval of Zepzelca® (Lurbinectedin for Injection) by China’s National Medical Products Administration for the Treatment of Small Cell Lung Cancer
28
2024-11
Luye Pharma’s Ruoxinlin and Other Drugs Included on China’s 2024 National Reimbursement Drug List
11
2024-11
Luye Pharma’s Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China
29
2024-08
Luye Pharma Announces 2024 Half Year Results
